Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

GRYT Health and Bristol Myers Squibb Team Up to Launch Diversity in Oncology Initiative

GRYT Health

In light of the health disparities in oncology, GRYT Health (“grit”), an oncology solutions company that was started and run by cancer survivors, and Bristol Myers Squibb, have partnered to launch Diversity in Oncology, a virtual platform available at www.diversityinoncology.com to highlight and raise awareness of the health disparities in oncology facing diverse patients in the U.S. As one example of a racial disparity that exists in oncology, according to the National Institute of Health, “The invasive breast cancer age-adjusted mortality rate for black women age <40 was twice that for white women.” The Diversity in Oncology initiative will co-create a series of live, interactive sessions that bring together a multi-stakeholder audience of local and national organizations, patients and caregivers, healthcare providers, clinical trial teams and principal investigators, schools of public health and others. The goal of the initiative is to have courageous conversations about what’s currently inequitable, so that this cross-stakeholder, cross-cultural initiative can work towards structural changes in clinical trials. By bringing together diverse patients who have experienced inequities, alongside those who run trials, we will highlight current inequities and identify ways to adapt the system. The first of four live sessions will be October 27, 2021, from 4:00 – 5:30pm ET and is titled “Experience of Diverse Patients and Families in Clinical Trials.” It will feature an opening keynote from Wendy Short Bartie, senior vice president, U.S. Oncology at Bristol Myers Squibb, followed by a panel conversation moderated by Megan-Claire Chase, partnership director at GRYT Health and equity advocate. The session will include “break-out” rooms where attendees will be able to interact with the speakers to ask questions and to share their own stories and experiences in cancer clinical trials. “This initiative is about acknowledgment of the real and current issues in cancer clinical trials that need to be fixed,” said Megan-Claire Chase, partnership director at GRYT Health and moderator of the first session on the Diversity in Oncology platform. “This initiative is being developed with the voices of the underrepresented communities living these experiences, so that resources and structural change can be co-designed together.” The panel speakers in the first session will share their own personal experiences - as patients participating in clinical trials, as well as those who chose not to participate in a clinical trial. “When I participated in a clinical trial for breast cancer, the research team never showed any care or concern to my questions,” said Venus Ginés, president and founder, Día de la Mujer Latina® Inc. and speaker on the Oct. 27 session of Diversity in Oncology. “When I shared about the side effects that I was struggling with - they would say ‘I will document it on your file,’ but there was no support or follow-up care. After three months, I left the trial and upon not getting a call-back, I felt it had been a waste of my time.” Venus founded Día de la Mujer Latina® Inc. not only to educate Latinas about breast and cervical cancer, but as a result of her experience. In her work, she teaches promotores/community health workers to be more patient-centered and respectful to their constituents and patients, providing timely responses, resources, and support. Upcoming sessions, all available on the same virtual platform, will focus on topics relevant to bringing awareness to and developing solutions for healthcare inequities, including the experience of diverse physicians, principal investigators in clinical research, improving representation of diversity in clinical trials, and new models of academia and community collaboration in terms of clinical research. The virtual platform will provide resources and access to organizations and individuals advancing health equity, as well as the opportunity to participate in the live, interactive sessions to foster discussion and collaboration. To register for free access to the platform and the series, visit www.DiversityinOncology.com. All sessions will be recorded and also available on demand. Source: Breast cancer epidemiology in blacks and whites: disparities in incidence, mortality, survival rates and histology (nih.gov) GRYT Health is a digital oncology company that empowers people to be in charge of their own health through education, engagement and support. We offer a community free from judgment that focuses on humanity and the value each person brings. Our mission is to improve quality of life and increase survival for people facing cancer through the relentless focus on patient experience. We put patients first and work with healthcare organizations that do the same. We use the patient voice to enhance drug development and access; and together, we are helping to move healthcare forward. Visit www.grythealth.com or www.solutions.grythealth.com to learn more. Contact Details Lindsay Barnes +1 215-410-9982 Lindsay.Barnes@evokegroup.com Company Website https://www.grythealth.com

October 14, 2021 11:52 AM Eastern Daylight Time

Image

Turning the Lights Out on Fluorescents

Clean Lighting Coalition

A new report released today by the Clean Lighting Coalition highlights the environmental and health risks posed when fluorescent lamps break, especially to vulnerable populations. The report provides concrete steps government, industry, consumers, and others, like childcare providers, can take to accelerate the transition to LED lighting, which is mercury-free, more energy-efficient, more cost-effective, and widely available. To mitigate the risks posed by mercury, the Coalition is calling on the Biden Administration to support the global phase-out of fluorescent lighting by 2025 at the upcoming meeting of the United Nation’s Minamata Convention on Mercury in March 2022. Furthermore, the Coalition notes that phasing out fluorescent lighting aligns with the Administration’s Executive Order on Tackling the Climate Crisis at Home and Abroad issued earlier this year. “Fluorescent lamps have been tolerated for decades because they were considered the most energy-efficient option,” said Alicia Culver, Executive Director of the Responsible Purchasing Network and co-author of the report. “But this is no longer the case: LEDs are twice as energy efficient as fluorescent lamps, last 2-3 times longer, and they don’t contain mercury.” The report details: Health risks to those exposed to mercury, especially populations that are more vulnerable, such as pregnant people and their unborn babies, infants and young children, communities of color, and those living in low-income neighborhoods Health risks to workers exposed to mercury when lamps break during the manufacturing, installation, recycling, and disposal of fluorescent lamps Environmental hazards posed by the release of mercury in fluorescent lighting Benefits of transitioning to LED lighting, now considered the most cost-effective and reliable lighting option in the U.S. marketplace “We know that mercury exposure, especially in early life, can lead to irreversible deficits in verbal skills, reduced attention span and motor control, and lower IQ,” said Michael T. Bender, director of the Mercury Policy Project and one of the report authors. “However, these exposure risks are avoidable by replacing fluorescents with LEDs.” The report recommends steps that government entities, businesses, and consumers can take to accelerate the transition to LEDs. For example, it recommends state and local governments: Adopt and enforce mercury reduction laws to phase out fluorescents. For example, Vermont law bans sales of mercury-containing lamps unless the manufacturer has demonstrated that no comparably performing alternative non-mercury energy-efficient lamp is available at a comparable cost. Update guidance, including on websites, to highlight the hazards of mercury in fluorescent lighting and the advantages of LEDs including reduced risk, better energy efficiency, longer product life, and significant cost savings. Adopt new lighting specifications that prohibit vendors from offering fluorescent lamps, fixtures and ballasts on their state supply contracts. Maryland and Minnesota are already using this approach to eliminate many fluorescent lighting products from their contracts. Develop contracts for environmentally preferable lighting equipment that offer a wide array of LED lighting products at discounted prices. New York State and the City of San Francisco have lighting contracts that feature LEDs. The report also highlights guidelines from the US EPA regarding strict protocols that should be taken when cleaning up broken fluorescent lamps. “There is no safe level of mercury exposure and following US EPA guidelines in cleaning up a broken lamp is not easy,” says Coalition Deputy Director Ana Maria Carreño. " Most people, for example, either don’t know about or find it difficult to follow the proper procedures. Yet, with the tremendous advances in LED technology during the past decade, there’s no reason to continue using fluorescent lighting.” Mercury is highly toxic to humans, which is why the World Health Organization lists it among the top 10 chemicals or groups of chemicals of major public health concern. “The U.S. has been a global leader on many fronts,” said Michael Scholand, LC, of the Coalition and one of a worlds-leading experts on lighting policy and technology. “But when it comes to taking action on fluorescent lighting, the U.S. lags behind some African countries and the European Union, which have already taken steps to phase out mercury-based lighting.” Mercury in Fluorescent Lighting: Unnecessary Health Risks and Actionable Solutions ” was published by the Clean Lighting Coalition in partnership with the Mercury Policy Project and the Responsible Purchasing Network. The report was co-published by the following groups: Vermont Public Interest Research Group, Healthy Babies Bright Futures, Eco-Healthy Child Care, the Children’s Environmental Health Network, Clean Water Action and Ecology Center. The Coalition is encouraging consumers, businesses, and others to sign a pledge to support the global transition to clean and efficient lighting, and to end the manufacture, export and import of mercury-containing fluorescent lighting in the United States by 2025. To learn more, visit https://cleanlightingcoalition.org/advocates-pledge. ____________ For more information about the transition away from mercury-based lighting, visit https://cleanlightingcoalition.org/benefits/ About the Clean Lighting Coalition The Clean Lighting Coalition is a global partnership coordinated by CLASP to capture the health and environmental benefits of eliminating mercury-based lighting. To learn more, visit www.cleanlightingcoalition.org and follow the Coalition on Twitter, Facebook, and LinkedIn. About the Mercury Policy Project Founded in 1998, the Mercury Policy Project promotes policies to eliminate mercury use and reduce mercury exposure. To learn more, visit www.mercurypolicy.org About the Responsible Purchasing Network Responsible Purchasing Network is an international network of buyers dedicated to socially responsible and environmentally sustainable purchasing. To learn more, visit www.responsiblepurchasing.org About Peter Maxson Mr. Maxson is an environmental consultant who has long provided expert advice on mercury to multinational organizations, government agencies, nongovernmental organizations, and others. Contact Details Clean Lighting Coalition Alexia Ross +1 339-222-4311 aross@clasp.ngo Clean Lighting Coalition Ana Maria Carreno +1 202-999-2886 acarreno@clasp.ngo Company Website https://www.cleanlightingcoalition.org

October 14, 2021 09:00 AM Eastern Daylight Time

Bay Area Mental Health adds Ketamine Assisted Psychotherapy to its Services as the Psychedelic Renaissance Booms

Bay Area Mental Health

California based mental health clinic, Bay Area Mental Health (BAMH) is officially announcing that they have added Ketamine Assisted Psychotherapy (KAP) to their offerings in order to better serve the needs of Silicon Valley and surrounding areas. Bay Area Mental Health is the first mental health clinic in Silicon Valley’s South Bay to offer Ketamine Assisted Psychotherapy, and is laying the foundation to provide additional psychedelic therapies as soon as they become available. For now, the only legal form of psychedelic-assisted psychotherapy uses ketamine, which is not a traditional psychedelic, but has mind-altering properties that have been found to relieve depression, anxiety and PTSD when used appropriately and under supervision of licensed professionals. The rates of depression, anxiety, PTSD and suicidality is continuing to climb. BAMH founder Linnea Butler states, “we have a mental health epidemic in the United States. More urgently than ever, we need new approaches to complex mental health problems that are not treated by talk therapy alone. Ketamine is safe, legal, and accessible and shows many of the same benefits as the more traditional, but largely inaccessible, psychedelic medicines. We have seen as much as a 70% reduction in symptoms over a 6 week course of ketamine assisted psychotherapy treatment and in one case we witnessed a near complete remission of trauma, depression and anxiety.” Butler specializes in treating complex trauma and mood disorders, and currently oversees Ketamine Assisted Psychotherapy at the clinic. Butler has been accepted into the MAPS MDMA Assisted Therapy training program and is on track to complete her certificate by the end of 2021. The results of a successful phase-three drug trial of MDMA Assisted Therapy were reported in May that showed that 67% of patients with PTSD were cured. MDMA will likely be available to clinics in the next 2 years, pending FDA approval. Butler stated, “it is critical that we work within the legally allowed and approved medicines and procedures, otherwise it becomes the wild west; emotional and physical safety is paramount”. Clients are evaluated psychologically and medically to ensure that they are appropriate for this treatment. This work is overseen by founder and licensed therapist, Linnea Butler, and integrative psychiatrist Dr. Sidney Edsall. A ketamine assisted psychotherapy session is typically 3 hours long and clients are attended to throughout the session. Sessions begin with preparation and setting the intention for the psychedelic experience, followed by self-administration of doctor-prescribed medicine, and finally processing and integration of the experience. The patient wears an eye mask and listens to specifically curated music to help guide the experience. Butler’s scientific background as a molecular biologist and geneticist has driven her to look deeply at the intersection between science and psychology. Butler explains, “we are on the cutting edge of mental health care, where neuroscience meets experiential treatment, spirituality and depth psychology. Talk therapy is no longer adequate to address the increasingly complex nature of mental health problems, where people often are struggling with more than one diagnosis. The need for a new paradigm is urgent.” Butler will be speaking about Ketamine Assisted Psychotherapy at an online event next month: “ Ketamine: The Science and Spirit of Psychedelic Healing “ About Bay Area Mental Health BAMH was founded in 2014 to treat people with complex mental health issues, including Trauma and complex PTSD, that often necessitate multiple different approaches and healing modalities. BAMH is dedicated to helping people with difficult problems using cutting edge approaches and collaborative care. Linnea Butler is a licensed marriage and family therapist and the founder of Bay Area Mental Health, Linnea specializes in treating complex trauma, has been featured on the Trauma Therapist Podcast, and was an Adjunct Professor at Sofia University and guest lecturer at Santa Clara University. Linnea received her M.S. degree in Genetics and Molecular Biology under the direction of Nobel Laureate Dr. Mario Cappechi, and her M.A. degree in Counseling Psychology from Institute of Transpersonal Psychology. Dr. Sidney Edsall is a board-certified psychiatrist and completed her residency at Stanford in integrative medicine. She integrates Western medical practices with Traditional Chinese Medicine by cultivating treatment plans using Western medicine terminology infused with Buddhist and Daoist philosophy. She also spent 4 years living and working abroad in Germany and Italy caring for active duty U.S. Army soldiers on U.S. military bases. For more information about mental health therapy services provided by BAMH, please visit the company website at: www.bayareamentalhealth.com Contact Details Bay Area Mental Health Linnea Butler, LMFT +1 669-240-5505 linnea@bayareamh.com Company Website https://www.bayareamh.com

October 14, 2021 09:00 AM Eastern Daylight Time

Video Image

Cepheid recibe el marcado CE para Xpert Xpress CoV-2/Flu/RSV plus

Cepheid

Cepheid anunció hoy que ha recibido el marcado CE para el ensayo Xpert Xpress CoV-2/Flu/RSV plus, una prueba de diagnóstico molecular rápido para la detección cualitativa de los virus que causan la COVID-19, la gripe A, la gripe B y el virus respiratorio sincitial (RSV) en una muestra única de paciente. La nueva versión plus de la prueba proporciona una tercera diana génica para la detección del virus SARS-CoV-2 con el fin de afrontar el problema de futuras mutaciones del virus. Xpert Xpress CoV-2/Flu/RSV plus está diseñada para utilizarse en cualquiera de los más de 35 000 sistemas GeneXpert ® de Cepheid existentes en todo el mundo y proporcionar resultados en aproximadamente 36 minutos. Durante la pandemia, en el mundo se han documentado diversas variantes del virus que causa la COVID-19. Los virus cambian constantemente mediante mutación, y con el tiempo se espera que aparezcan nuevas variantes. La adición de una 3ª diana génica a la versión plus de la prueba CoV-2/Flu/RSV de Cepheid proporciona una cobertura más amplia para mitigar los posibles efectos de las futuras variaciones genéticas del virus. «En esta temporada de enfermedades respiratorias, el personal sanitario puede enfrentarse a diversas infecciones víricas que cursan con síntomas similares a los de la COVID-19, como la gripe A y B, y el virus respiratorio sincitial. Disponer de una prueba rápida y precisa, diseñada para detectar las variantes actuales y futuras de los virus que causan la COVID-19 y la gripe será cada vez más importante», afirmó el Dr. David Persing, MD, Ph.D., Director médico y tecnológico de Cepheid. «La posibilidad de recoger una muestra y realizar una única prueba multiplex de alta sensibilidad que detecte y distinga los cuatro virus proporcionará resultados prácticos para tomar mejores decisiones en primera línea en nuestros sistemas sanitarios». Se espera que esta semana se empiece a enviar ya la prueba Xpert Xpress CoV-2/Flu/RSV plus a los países que acepten productos con marcado CE. Visite https://www.cepheid.com/en para obtener más información, vídeos y prospectos. Para consultas a Cepheid, relacionadas con los medios de comunicación, contacte con: Darwa Peterson darwa.peterson@cepheid.com Acerca de Cepheid Cepheid, con sede en Sunnyvale, Calif., Cepheid es una empresa líder en diagnóstico molecular. Cepheid tiene el compromiso de mejorar la atención sanitaria mediante el desarrollo, la fabricación y la comercialización de sistemas y pruebas moleculares precisos y fáciles de utilizar. Con la automatización de procesos manuales sumamente complejos y laboriosos, las soluciones de la empresa ofrecen a las instituciones de cualquier tamaño una mejor manera de realizar pruebas de diagnóstico molecular sofisticadas para la detección de microorganismos y enfermedades genéticas. Aprovechando sus extensas capacidades en biología molecular, el trabajo de la empresa se centra en aquellas aplicaciones en las que más se necesitan resultados precisos, rápidos y fiables, como el control de las enfermedades infecciosas y el cáncer. Para obtener más información, visite http://www.cepheid.com. Contact Details kdm communcations Sarah Khan +44 1480 405333 sarahk@kdm-communications.com Company Website https://www.cepheid.com/en

October 14, 2021 08:10 AM Eastern Daylight Time

Image

Holland & Barrett backs Floe Oral Care to tackle gum disease via salivary biomarkers

Floe Oral Care

Floe Oral Care, the oral healthcare business dedicated to improving oral and systemic health by means of a direct-to-consumer subscription, has secured £350k from a group of high profile investors including Holland & Barrett, Lord Mervyn Davies, Tim Farazmand, Professor John Deanfield CBE, Sir Nigel Rudd, and Julio Bruno. Existing shareholders Stephen Welton, Dr. Jose Navarro, and Charles Southey are also following on. Founded by Anglo-Spanish duo Will Welton and Javier Navarro, Floe is an online subscription service on a mission to address the UK’s ‘dental care timebomb’ by building a preventative routine for consumers and providing vital insights into undetected gum disease. Will Welton, Co-founder at Floe Oral Care said: “If your mouth is the gateway to your body, then protecting it requires not only using the right products but also visibility of what condition your gums are in. The impact of gum disease is significant, and the prevalence of periodontitis has barely changed over the last 20 years. Our mission is to build a service that both tracks and improves oral and systemic health. We want to encourage a pro-active relationship with dental care by capturing and contextualising oral health data, and are thrilled to be bringing on board a fantastic group of investors from business and healthcare as well as an excellent and highly relevant corporate partner. This is a great platform for the next stage of our development” Periodontitis is now the sixth most prevalent disease in the world, and according to research led by The Economist Intelligence Unit (IEU), costs the UK £6.4bn a year in treatment. Nearly half the adults in the UK have some form of periodontal disease, which has increasingly been shown to raise the risk of serious health conditions including cardiovascular disease and diabetes. Its awareness has remained low however amongst the general public and other health professionals - it’s often referred to as a silent killer - with the study showing that three out of four adults with periodontitis do not know they have the condition at all. Tamara Rajah MBE, Chief Business & Science Officer, Holland and Barrett: “H&B are committed to making health and wellness a way of life for everyone, and to supporting early-stage innovation in wellness as part of our strategy. Recognising that effective oral health management can disproportionately impact an individual’s overall health and wellness, coupled with our interest about the potential of diagnostics, makes Floe very exciting for us. We look forward to working with Will, Javier and the team at Floe to optimise the way we manage our oral health and improve lives.” Floe is building a data driven approach, designed to cast light on untreated periodontitis and put the right measures in place to improve it. The service will track gum health via proprietary at home saliva testing whilst delivering essential products to support your oral health. Floe launched their core dental kit in August 2020, delivering their own unique toothpaste formulations (Dusk and Dawn), an ultra-soft toothbrush, and charcoal dental floss, delivered every three months to improve preventative habits in a more sustainable way. The products are all built with the environment in mind, including a free-returns service collecting used products for specialist recycling when subscribers' new boxes arrive. Julio Bruno, CEO of Time Out Group plc, will be joining the board as a Non-Executive Director whilst Stephen Welton, founder and Executive Chairman of BGF, the UK’s largest growth capital investor, will remain as the Chairman. Professor John Deanfield CBE joins Floe as Chief Medical Officer, to put together a world leading Advisory Board to inform the strategy of the saliva testing and future healthcare products. Professor Deanfield is one of the leading cardiologists in the UK and has published several papers on the linkage between oral and systemic health. Professor John Deanfield CBE commented: “We now understand the big impact oral health can have on important diseases in the rest of the body. This underpins a new opportunity to benefit from a change in approach to oral health – I am excited to be joining Floe to help address this.” About Floe Oral Care Floe Oral Care is a subscription service providing core dental products/ services on a quarterly basis with a closed loop recycling process to ensure that plastic doesn’t end up in the ocean. It was co-founded by William Welton and Javier Navarro to deliver technology enabled dental healthcare solutions whilst protecting the planet’s environment. Javier comes from a family of dentists and spent the first part of his career in banking. Will’s background is in consumer goods with commercial roles within the drinks industry and e-commerce. For careers please get in touch via CV and covering letter to hello@getfloe.com. About Holland & Barrett Holland & Barrett is the UK’s leading wellness retailer* and one of the largest in Europe. We make health and wellness and way of life for everyone, with a leading range of own brand, innovative vitamins, supplements, specialist food, sports nutrition and ethical beauty brands. Established in 1870, Holland & Barrett has been trusted for wellness for over 150 years and is owned by the Letter One Retail Group (L1 Retail). Holland & Barrett has a retail presence of more than 1000 stores across 16 countries worldwide, including over 800 in the UK and Ireland**, as well as a rapidly expanding e-commerce business. Holland & Barrett’s colleagues are “qualified to advise” with in depth training in nutrition and supplements to give accessible personalised advice to customers on their individual needs. *Kantar Brand Tracking – health and wellness retailers March 2021 ** up to 30 September 2020. Contact Details Floe Oral Care Bilal Mahmood +44 7714 007257 bilal@getfloe.com Company Website https://getfloe.com/

October 13, 2021 08:00 AM Eastern Daylight Time

Image

It’s Flu and Cold Season: How Over-the-Counter Remedies Can Help Relieve Cough and Chest Congestion

YourUpdateTV

As influenza activity begins to increase in October, now is the time to know how to navigate this cold and flu season. Recently, New York Times bestselling author, Dr. Ian Smith teamed with Mucinex and YourUpdateTV on a satellite media tour to discuss how to relieve cold, cough, and chest congestion symptoms. A video accompanying this announcement is available at: https://youtu.be/vfd-KUPmT3U While seasonal influenza viruses are detected year-round, flu viruses are most common during the fall and winter – kicking off in October. So, as we enter another unprecedented cold & flu season, we can still expect to see an increase in cold and flu cases between now and February. That said, according to Dr. Ian Smith, we should still continue to take key preventative measures to avoid catching any of these viruses. This includes wearing a mask in crowded public places, washing your hands often and covering your nose and mouth with a tissue or your elbow when you cough and sneeze to prevent the spread of germs. While there is no cure for the common cold or flu, there are over-the-counter medications that can help when you start to feel those classic cold and flu symptoms coming on. For instance, Mucinex has a line of 12-hour products that provide relief. Mucinex DM not only thins and loosens mucus, but also controls cough, providing relief for both wet and dry coughs, lasting up to 12 hours. And Mucinex 12 HR Extended Release Tablets help thin and loosen mucus to relieve chest congestion, and also provide relief for 12 hours. People must use over-the-counter products as directed. If your cold and flu symptoms persist, you should contact your healthcare professional and get checked out if deemed necessary. Dr. Smith also shared self-care recommendations such as exercising regularly and eating healthy. Activities like walking, strength training and yoga are good for the mind and the body. A diet full of nutritious meals packed with fruits and veggies and lean proteins like chicken or fish is also very important for a strong immune system. For more information on how to take care of yourself this cold and flu season, visit Mucinex.com for more information. About Dr. Dr Ian Smith: Dr. Ian Smith is the author of the #1 New York Times bestselling books, SHRED: THE REVOLUTIONARY DIET, and SUPER SHRED: The Big Results Diet, and BLAST THE SUGAR OUT. Dr. Smith’s highly anticipated newest book, The Clean 20, became an instant New York Times best seller, helping hundreds of thousands of people reduce bad sugars from their diet, lose weight, lower blood sugar levels, and cut the cravings. Dr. Smith was appointed by President Obama to a second term on the prestigious President’s Council on Fitness, Sports, and Nutrition. He is currently the medical contributor and co-host of the nationally syndicated television show The Rachael Ray Show. He is a former co-host of the Emmy award winning syndicated daytime talk show, The Doctors. He also served as the medical/diet expert for six seasons on VH1’s highly-rated Celebrity Fit Club, and is the creator and founder of the national health initiatives The 50 Million Pound Challenge and The Makeover Mile. Dr. Smith is the former medical correspondent for NBC News network and for NewsChannel 4 in New York, where he filed reports for NBC Nightly News and The Today Show as well as WNBC’s various news broadcasts. He has appeared extensively on various broadcasts including The Oprah Winfrey Show, The View, Dr. Oz, Steve Harvey Show, The Talk, Larry King Live, Anderson Cooper 360, CNN, MSNBC and many more. He has written for various publications including Time, Newsweek, Men’s Fitness, and the New York Daily News, and has been featured in several other publications including, People, Redbook, Details Magazine, Essence, Ebony, University of Chicago Medicine on the Midway, Cosmopolitan, and Black Enterprise. About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

October 12, 2021 11:09 AM Eastern Daylight Time

Video

Kadimastem Holds Successful Preliminary Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing cell therapy treatments for ALS and diabetes, announced today that the Company held a preliminary meeting with the FDA (INTERACT) on October 7, 2021 regarding IsletRx, the company’s cell therapy product in development for the treatment of diabetes. During the meeting, Kadimastem received a response document from the FDA noting that the company’s clinical development plan for IsletRx was being positively considered. It also included constructive comments and guidelines applicable for the next step pre-IND submission. This interaction is of great importance to Kadimastem’s clinical product development process and is an important milestone for the company. It was Kadimastem’s first meeting with the FDA regarding its diabetes project and the FDA’s first review of IsletRx, which demonstrated positive results in preclinical trials. IsletRx is an expanded population of allogeneic stem cells differentiated into functioning insulin producing pancreatic islet cells. The company then uses a proprietary technology to select the purest performing cells from its population and puts them into a microcapsule that protects the cells from being rejected by the body’s immune system. The implanted cells have shown in preclinical studies to be able to detect the sugar levels in the body and to, produce, and secrete, on demand, the required amounts of insulin and glucagon, just like a healthy pancreas. Kadimastem CEO Asaf Shiloni said, "Thanks to Dr. Kfir Molakandov, the Director of Diabetes at Kadimastem, who presented the IsletRx project in an impressive manner, we received a positive response to the company’s clinical development outline from the FDA's expert team, who we believe were overall very impressed with our technology. The FDA’s expert team provided us with important feedback that we will use to prepare for the next step, our Pre-IND submission for IsletRx. I am convinced that the successful meeting and the relevant feedback will contribute to the continued progress of our product development and if all goes well, ultimately provide a cure for those living with diabetes.” Kadimastem Chief Scientist Professor Michel Revel said, “The INTERACT meeting with the FDA is an important step forward and shows that Kadimastem's development plan for its diabetes treatment product, IsletRx, is in the right direction.” About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to cure patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. An INTERACT meeting took place with the FDA on October 7, 2021 where the diabetes treatment program was discussed and the company received directions how to prepare its Pre-IND submission. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Must Have Communications Marjie Hadad marjie@mhc-pr.com Kadimastem Sarah Herzl +972 73-797-1613 s.herzl@kadimastem.com Company Website https://www.kadimastem.com/

October 12, 2021 09:54 AM Eastern Daylight Time

Jamie Lee Curtis to Receive The 2021 Shatterproof Brian Mendell Memorial Award

Shatterproof

Shatterproof, a national nonprofit organization dedicated to reversing the addiction crisis across the United States, is presenting the 2021 Shatterproof Brian Mendell Memorial Award to actress, Jamie Lee Curtis. Curtis will receive the award at The Shatterproof Chairman’s Reception will be held virtually on October 20, 2021, at 6:30 PM ET. Shatterproof was founded by Gary Mendell in 2013 after losing his son Brian Mendell to the disease of addiction. This year’s Chairman’s Reception is taking place on the 10-year anniversary of the death of. The Shatterproof Brian Mendell Memorial Award is given to someone who is making change to end addiction stigma through their work and by using their voice. Curtis embodies this with her 22 years in recovery from substance use disorder. She uses her platform as well-respected member of the entertainment industry to speak out bravely concerning addiction and openly sharing her story. “Jamie Lee exemplifies leadership in recovery and her leadership powerfully impacts breaking down stigma. By openly and honestly sharing her journey from addiction to a full, vibrant life in recovery, she is sharing a message of courage and hope. Shatterproof is honored to have Jamie receive this year’s award on the ten-year anniversary of the passing of my son,” said Gary Mendell, founder & CEO, Shatterproof. “I am humbled and honored to receive The 2021 Shatterproof Brian Mendell Award. Shatterproof is doing life-saving work that is making systemic changes to how people talk, treat and recover from addiction. It is so important that those of us in recovery share our stories to help end the unjust shame and stigma that surrounds this health crisis,” said Jamie Lee Curtis. The Shatterproof Chairman’s Reception is open to all who will to join us as the organization gathers as a community to celebrate a year of groundbreaking progress, and honor Golden Globe winning actress, Jamie Lee Curtis for her contributions to the cause. The emcee will be Craig Melvin of NBC News’ TODAY and author of Pops: Learning to be a Son and a Father. Registration for the event is still open at www.chairmansreception.org. About Shatterproof: Shatterproof is a national nonprofit organization dedicated to reversing the addiction crisis in the United States. Shatterproof harnesses the models of business, the rigor of science and the power of a national movement to create change and save lives through three pillars of work: revolutionizing the addiction treatment system, breaking down addiction-related stigmas and supporting and empowering our communities. To learn more visit www.Shatterproof.org. Contact Details Kirsten Seckler +1 203-247-0615 kseckler@shatterproof.org Company Website https://www.shatterproof.org/

October 12, 2021 09:07 AM Eastern Daylight Time

US Digestive Health Announces Pilot with AI-Enhanced Endoscopy Aid Device, GI Genius

US Digestive Health

US Digestive Health, a management services organization created to expand access to high-quality, value-based gastroenterology care, began a trial with GI Genius, a state-of-the-art AI-enhanced endoscopy aid device for the detection of colorectal lesions during colonoscopy. GI Genius utilizes artificial intelligence to improve detection of colorectal cancer during screening colonoscopy procedures. Medtronic received approval from the FDA in April of this year. US Digestive Health initiated a trial of the new technology in July 2021 and is the first practice in Pennsylvania to offer GI Genius. “We are constantly researching and investing in ways to help our providers detect potentially cancerous lesions,” said Dr. Dale Whitebloom, Chief Medical Officer of US Digestive Health. “We want the very best for our patients and if AI helps us to detect cancerous and precancerous lesions more effectively then we want to explore it thoroughly.” GI Genius is a combination of hardware and software that helps identify regions of interest during the colonoscopy. The device is not intended to replace lab sampling or suggest a course of action to the physician – but it does aid in highlighting areas of concern for providers to address. “US Digestive Health is committed to bringing the latest advances in colorectal cancer screening to our communities,” said Jerry Tillinger, CEO of US Digestive Health. “We are proud to be the first practice in Pennsylvania to deploy this incredible technology for our patients.” With offices throughout Central and Southeastern Pennsylvania, including the Greater Philadelphia region, US Digestive Health works hand-in-hand with gastroenterology partner practices to meet the challenges of a fast-changing healthcare landscape. By providing innovative business management and technology solutions that ease administrative burdens and support their financial success, US Digestive Health allows physicians to stay focused on delivering great patient care. US Digestive Health was formed in 2019 by Amulet Capital Partners, LP (“Amulet”), a healthcare private equity investment firm based in Greenwich, Connecticut, in partnership with member practice partner physicians. For more information, visit https://usdigestivehealth.com/ About US Digestive Health As the leading gastroenterology practice on the East Coast, US Digestive Health is at the forefront of the rapidly advancing science of digestive health, bringing new insight into the care, treatment and prevention of digestive health disorders. For more information, visit https://usdigestivehealth.com. About Amulet Capital Partners, LP Amulet Capital Partners, LP is a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in companies. Amulet Capital Partners focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size generally between $25 million to $150 million. For additional information, please visit www.amuletcapital.com. Media Contact for Amulet Capital Partners, LP Melissa Sheer Kent Place Communications, LLC 917-690-2199 melissa@kentplacellc.com Contact Details Noah Ramagano nramagano@usdhealth.com Company Website https://usdigestivehealth.com

October 12, 2021 07:56 AM Eastern Daylight Time

1 ... 249 250 251 252 253 ... 302